Secondary prevention of venous thromboembolic complications. Focus on dabigatrane

2017

Амбулаторная хирургия, Vol 0, Iss 3-4, Pp 36-42 (2017)

Venous thromboembolic complications (VTEC) are a frequent pathology accompanied by high lethality. After VTEC the risk of their recurrence not equivalent for all patients remains. The anticoagulant therapy available currently effectively prevents VTEC increasing a possibility of hemorrhages. This means that at planning the secondary prevention it’s necessary to maintain the optimal balance between a possibility of recurrence of VTEC and development of hemorrhagic complications. Thus, selection of patients for secondary prevention must be accompanied by a comprehensive analysis of numerous factors as determining the possibility of VTEC recurrence as well as a risk of complications development. Warfarin is the most frequently used drug for long-term anticoagulant per os therapy, it requires frequent monitoring with periodic dose correction and strict dietary limitations. New oral anticoagulants (NOAC) are applied at a fixed dose without obligatory strict hemostasiologic control, which makes them rather attractive for continues secondary prevention of VTEC.

article

Russian

Remedium Group LTD, 2017.

тромбоз глубоких вен, тромбоэмболия легочной артерии, венозные тромбоэмболические осложнения, тгв, тэла, втэо, ноак, дабигатран, антикоагулянты, Surgery, RD1-811